MARKET

ALPMY

ALPMY

Astellas Pharma
OTCPK
16.38
-0.10
-0.61%
Closed 15:59 04/06 EDT
OPEN
16.40
PREV CLOSE
16.48
HIGH
16.58
LOW
16.31
VOLUME
8.03K
TURNOVER
132.00K
52 WEEK HIGH
16.87
52 WEEK LOW
8.05
MARKET CAP
29.34B
P/E (TTM)
14.25
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ALPMY last week (0330-0403)?
Weekly Report · 1d ago
ORIC Pharma drops after early-stage trial data for prostate cancer therapy
Seeking Alpha · 5d ago
Weekly Report: what happened at ALPMY last week (0323-0327)?
Weekly Report · 03/30 09:27
Jefferies Keeps Their Buy Rating on Astellas Pharma (ALPMF)
TipRanks · 03/24 10:19
J.P. Morgan Sticks to Its Hold Rating for Astellas Pharma (ALPMF)
TipRanks · 03/23 10:16
Weekly Report: what happened at ALPMY last week (0316-0320)?
Weekly Report · 03/23 09:25
Pfizer posts late-stage trial win for Talzenna plus Xtandi in new prostate cancer indication
Seeking Alpha · 03/19 11:44
Astellas Pharma (ALPMF) Receives a Hold from Mizuho Securities
TipRanks · 03/19 10:16
More
About ALPMY
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.

Webull offers Astellas Pharma Inc stock information, including OTCPK: ALPMY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALPMY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALPMY stock methods without spending real money on the virtual paper trading platform.